Our long-term experience in supporting multidisciplinary drug discovery teams in the pharmaceutical industry with drug metabolism and PK consultancies means we can support you by working as an integral part of your discovery team or with stand-alone functions. We offer our services to academia, CROs, biotechnological and pharmaceutical companies, and life science venture capital funds.
We can support your project in any stage of drug discovery, from early hit identification through preclinical candidate profiling, including human PK prediction and prediction of an efficacious human dose based on a suggested PK/pharmacodynamic (PD) relationship.
Our goal is to help identify and characterize drug candidates with a predicted human PK sufficient to meet the desired target product profile, identify DMPK-related risks early in the process, and offer problem-solving solutions using standard high-throughput assays or tailor-made solutions.
We can review research proposals or due diligence packages with regard to DMPK and absorption, distribution, metabolism, and excretion (ADME) related risks (e.g., risk of insufficient absorption, exposure, and drug–drug interactions [DDIs]) and offer solutions for how to further define or de-risk them.
